Proceedings of the National Academy of Sciences: Licorice root found to contain anti-diabetic substance

April 2012
Biomedical Market Newsletter;4/21/2012, Vol. 21, p1
The article focuses on a research, in which researchers have discovered an anti-diabetic substance in the amorfrutin class of natural substances from Licorice root.


Related Articles

  • Troglitazone for insulin-resistant diabetes.  // American Family Physician;4/1/1997, Vol. 55 Issue 5, p1985 

    Presents information about the approval of the Food and Drug Administration on troglitazone (Rezulin) as the first anti-diabetes drug that targets the underlying cause of type II diabetes mellitus. Required dosage of troglitazone for patients receiving insulin injection; Most common adverse...

  • Improved Postprandial Glycemic Control With Insulin Aspart. Lindholm, Anders; McEwen, John; Riis, Anders P. // Diabetes Care;May99, Vol. 22 Issue 5, p801 

    Presents information on a study which compared the postprandial serum glucose control after administration of insulin aspart, a rapid-acting insulin analog, with that of unmodified human insulin in patients with type one diabetes. Research design and methods; Results; Conclusions.

  • In This Issue of Diabetes Care. Resnick, Helaine E. // Diabetes Care;Oct2014, Vol. 37 Issue 10, p2663 

    The article discusses various reports published within this issue including one on a study on the effect of albiglutide on diabetic patients, one on the importance of HbA testing to patients with diabetes and one on the effect of fetal hyperglycemia exposure on patients with gestational diabetes...

  • Antihyperglycemia and Antihyperlipidemia Effect of Protoberberine Alkaloids From Rhizoma Coptidis in HepG2 Cell and Diabetic KK-Ay Mice. Ma, Hang; Hu, Yinran; Zou, Zongyao; Feng, Min; Ye, Xiaoli; Li, Xuegang // Drug Development Research;Jun2016, Vol. 77 Issue 4, p163 

    Rhizoma Coptidis (RC), the root of Coptis chinensis Franch, a species in the genus Coptis (family Ranunculaceae), has been commonly prescribed for the treatment of diabetes in Chinese traditional herbal medicine applications. The present study is focused on the assessment of the...

  • Development of an Osmotically Controlled Drug-Delivery System of Glipizide. Patel, Ritesh B.; Patel, Rakesh P.; Patel, Madhabhai M. // Pharmaceutical Technology;Nov2010, Vol. 34 Issue 11, p80 

    Glipizide (GLZ), an oral hypoglycemic agent, is commonly prescribed for the treatment of patients with Type II diabetes mellitus. It is practically insoluble in water, but has a fractional bioavailability close to 1. The authors describe the development of an inclusion complex of GLZ with...

  • Changes in HbA1c, body weight, and systolic blood pressure in type 2 diabetes patients initiating dapagliflozin therapy: a primary care database study. Scheerer, Markus F.; Rist, Roland; Proske, Orm; Meng, Annika; Kostev, Karel // Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy;Oct2016, Vol. 9, p337 

    Aims: To investigate changes in glycated hemoglobin (HbA1c), body weight (BW), and systolic blood pressure (SBP) in type 2 diabetes (T2D) primary care patients initiating dapagliflozin treatment. Methods: T2D patients who started dapagliflozin in 985 general and 32 diabetologist practices...

  • Obesity, Inflammation, and Insulin Resistance – A Mini-Review. Zeyda, Maximilian; Stulnig, Thomas M. // Gerontology;Jul2009, Vol. 55 Issue 4, p379 

    The association of obesity, insulin resistance, and chronic low-grade inflammation has been evident for several years by now. Since obesity, insulin resistance, and inflammation all are related to aging as well, the mechanisms underlying this association are of critical importance for...

  • Metformin: An Old Drug for the Treatment of Diabetes but a New Drug for the Protection of the Endothelium. Kinaan, Mustafa; Ding, Hong; Triggle, Chris R. // Medical Principles & Practice;Jul2015, Vol. 24 Issue 5, p401 

    The anti-diabetic and oral hypoglycaemic agent metformin, first used clinically in 1958, is today the first choice or 'gold standard' drug for the treatment of type 2 diabetes and polycystic ovary disease. Of particular importance for the treatment of diabetes, metformin affords protection...

  • Evaluation of the Effects of Nateglinide on Postprandial Glycemia in Patients with Type 2 Diabetes mellitus: A Multicenter, Multinational, Non-Randomized, Non-Controlled Latin American Study. Islas-Andrade, Sergio; Revilla-Monsalve, Maria Cristina; Caminos, Quenemari R.; Chacín, Luis F.; Yupanqui, Hernán; López, Gloria; de la Torre, Walter; de Hurtado, Evelyn Martínez // Pharmacology;Jun2003, Vol. 68 Issue 2, p89 

    One hundred and sixteen Latin American type two diabetic patients previously only on a diet were enrolled in this multicenter, multinational, nonrandomized, noncontrolled study. Only 109 completed the study. After eight weeks of treatment with 120 mg of nateglinide, administered prior to each...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics